Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
February 2016
-
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions… -
Media Release
Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des… -
Story From Our Labs
CRISPR genome editing fuels cancer drug discovery
Genome editing advances drug discovery in biomedical research.
-
Media Release
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult… -
Media Release
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or… -
Story Access to Healthcare
Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.
-
In The News
Joe Jimenez on how to improve healthcare
In an op ed with Foreign Affairs, Joe Jimenez explains why outcomes, innovation and collaboration are the keys to improving healthcare worldwide. -
Story From Our Labs
Rediscovering the power of nature’s exquisite complexity
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
-
Media Release
Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA
Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU… -
Story Discovery
Intractable tumor cells crippled
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
-
Media Release
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
Sandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,… -
Story Discovery
Leveraging the liver’s ability to heal scarred tissue
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.